DJIA 16,374.76 23.38 0.14%
NASDAQ 4,733.50 -16.48 -0.35%
S&P 500 1,951.13 2.27 0.12%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

51.57 -0.18 (-0.35%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $51.57 -0.35%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $51.92
Previous Close $51.75
Daily Range $51.18 - $52.86
52-Week Range $35.26 - $77.80
Market Cap $6.2B
P/E Ratio 272.37
Dividend (Yield) $0.00 (0.0%)
Volume 2,033,948
Average Daily Volume 1,774,022
Current FY EPS -$0.52

Sector

Healthcare

Industry

Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary Rss Feed

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

3 Promising Biotechs Hobbled By First-Impression Issues

Isis Pharmaceuticals Enters Oversold Territory (ISIS)

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals (ISIS) Earnings Report: Q2 2015 Conference Call Transcript

Isis Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2015 Results - Earnings Call Transcript

Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape

Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

See More ISIS News...

ISIS's Top Competitors

ISIS $51.57 (-0.35%)
Current stock: ISIS
AMGN $149.23 (-2.01%)
Current stock: AMGN
GILD $101.91 (-2.26%)
Current stock: GILD
BIIB $301.63 (-0.85%)
Current stock: BIIB